Back to top
more

Ekso Bionics (EKSO)

(Delayed Data from NSDQ)

$8.73 USD

8.73
154,096

-0.33 (-3.64%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $8.69 -0.04 (-0.46%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 243)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of +4.73% and +0.13%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Five Below, Novo Nordisk, Ekso in Focus

by Abhinab Dasgupta

FIVE, NVO and EKSO led gains as Zacks strategies beat the S&P 500, highlighting upgrades, focus lists and model portfolios.

Zacks Equity Research

Ekso Bionics (EKSO) Upgraded to Buy: Here's Why

by Zacks Equity Research

Ekso Bionics (EKSO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of +45.45% and +8.11%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ekso Bionics (EKSO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Ekso Bionics (EKSO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Ekso Bionics (EKSO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -3.33% and -55.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -9.09% and 28.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -25% and 31.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?